December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Development of a Lentiviral Vector Harboring the Kringle 1-5 Domains of Human Plasminogen as an Agent to Treat Ophthalmic Neovascular Disease
Author Affiliations & Notes
  • SM Rooney
    Casey Eye Institute Oregon Health & Science University Portland OR
  • S Chen
    Casey Eye Institute Oregon Health & Science University Portland OR
  • R Murthy
    Casey Eye Institute Oregon Health & Science University Portland OR
  • T McFarland
    Casey Eye Institute Oregon Health & Science University Portland OR
  • B Appukuttan
    Casey Eye Institute Oregon Health & Science University Portland OR
  • JT Stout
    Casey Eye Institute Oregon Health & Science University Portland OR
  • Footnotes
    Commercial Relationships   S.M. Rooney, None; S. Chen, None; R. Murthy, None; T. McFarland, None; B. Appukuttan, None; J.T. Stout, None. Grant Identification: Clayton Foundation for Research and Research to Prevent Blindness
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1866. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SM Rooney, S Chen, R Murthy, T McFarland, B Appukuttan, JT Stout; Development of a Lentiviral Vector Harboring the Kringle 1-5 Domains of Human Plasminogen as an Agent to Treat Ophthalmic Neovascular Disease . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1866.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To develop a lentiviral vector capable of promoting the expression of a potential angiogenesis inhibitor composed of the five kringle domains of human plasminogen (K1-5). Methods:A cDNA coding for the 452 amino acid protein K1-5 was cloned into the lentiviral vector pHR'-IRES-eGFP under the control of the EF-1α/HTLV promoter. Replication-defective K1-5 lentivirus was prepared by three plasmid co-transfection into 293T cells. Transcription of this gene produces a bicistronic message, capable of the independent translation of K1-5 and eGFP proteins. Expression of K1-5 in human microvascular endothelial cells transduced with this virus was analyzed by RT-PCR analysis. To assay the angiogenic potential of this reagent, nylon mesh soaked with either the pHR'-EF1α/HTLV-K1-5-IRES-eGFP virus or pHR'-IRES-eGFP (a K1-5-deficient control) virus was inserted into a corneal stromal pocket in right and left eyes, respectively, of New Zealand White rabbits by a single blinded surgeon and removed after 24 hours. Corneas were insulted with standardized alkali burns 14 days after transduction. Analysis of the development of corneal vascularization by a single blinded observer is underway. Results:Expression of K1-5 in human microvascular endothelial cells transduced with this vector was proven by RT-PCR. On the third post-insult day an average of 0.3 mm2 of neovascularization was evident in K1-5-virus treated eyes, compared with 5.5 mm2 of neovascularization in control eyes. On day 5 this trend was reversed, with an average of 1.5-fold more vessels in the K1-5-treated eyes compared with controls. Immunohistologic correlation of the development of corneal neovascularization with the temporal and spatial characteristics of K1-5 expression is underway. Conclusion:We have developed a lentiviral reagent capable of transferring an expressible gene containing the five kringle domains of human plasminogen. This reagent may prove useful as an inhibitor of ocular angiogenesis.

Keywords: 419 gene transfer/gene therapy • 483 neovascularization • 370 cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×